Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.021
Sell
RSI(14)
44.589
Neutral
STOCH(KDJ)(9,3,3)
28.000
Sell
ATR(14)
0.274
High Vlolatility
CCI(14)
-84.952
Neutral
Williams %R
79.592
Sell
TRIX(12,20)
0.052
Sell
StochRSI(14)
0.000
Sell
Search
Protara Therapeutics Inc
TARAAdd to Watchlist
5.100USD
-0.200-3.77%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
196.80MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Protara Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Protara Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Protara Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Protara Therapeutics Inc Highlights
StrengthsRisks
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -3.76, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 46.80M shares, increasing 21.22% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 266.81K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.44.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
26.167
Target Price
+413.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Protara Therapeutics Inc is 7.14, ranking 120 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.93
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.04
Protara Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Protara Therapeutics Inc is 7.05, ranking 172 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.76, which is -95.11% below the recent high of -0.18 and -44.58% above the recent low of -5.43.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 68/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Protara Therapeutics Inc is 8.25, ranking 143 out of 382 in the Biotechnology & Medical Research industry. The average price target is 25.00, with a high of 30.00 and a low of 21.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
26.167
Target Price
+413.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Protara Therapeutics Inc
TARA
8
CRISPR Therapeutics AG
CRSP
29
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Protara Therapeutics Inc is 6.87, ranking 135 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.54 and the support level at 4.80, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
5.204
Sell
MA10
5.318
Sell
MA20
5.274
Sell
MA50
5.263
Sell
MA100
5.661
Sell
MA200
5.127
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Protara Therapeutics Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 85.08%, representing a quarter-over-quarter increase of 61.63%. The largest institutional shareholder is James Simons, holding a total of 125.70K shares, representing 0.23% of shares outstanding, with 31.93% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Protara Therapeutics Inc is 3.34, ranking 141 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.51
VaR
+6.49%
240-Day Maximum Drawdown
+35.85%
240-Day Volatility
+79.61%
Return
Best Daily Return
60 days
+10.23%
120 days
+12.73%
5 years
+70.06%
Worst Daily Return
60 days
-26.38%
120 days
-26.38%
5 years
-26.38%
Sharpe Ratio
60 days
-0.94
120 days
-0.29
5 years
+0.28
Risk Assessment
Maximum Drawdown
240 days
+35.85%
3 years
+66.46%
5 years
+86.59%
Return-to-Drawdown Ratio
240 days
+1.52
3 years
+0.54
5 years
-0.08
Skewness
240 days
+0.21
3 years
+2.83
5 years
+2.42
Volatility
Realised Volatility
240 days
+79.61%
5 years
+100.48%
Standardised True Range
240 days
+6.53%
5 years
+5.72%
Downside Risk-Adjusted Return
120 days
-34.84%
240 days
-34.84%
Maximum Daily Upside Volatility
60 days
+59.61%
Maximum Daily Downside Volatility
60 days
+61.94%
Liquidity
Average Turnover Rate
60 days
+2.45%
120 days
+2.52%
5 years
--
Turnover Deviation
20 days
-41.41%
60 days
-16.28%
120 days
-13.96%
Peer Comparison
Biotechnology & Medical Research
Protara Therapeutics Inc
TARA
6.90 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
